PDL BIOPHARMA, INC. Uncategorized Contracts & Agreements

35 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
PDL BIOPHARMA, INC.
Biotechnology
2021
Asset Transfer Agreement dated as of August 11, 2020 between Defined Diagnostics, LLC (F/K/A Wellstat Diagnostics LLC) and the
PDL BIOPHARMA, INC.
Biotechnology
NY
2020
Tax Matters Agreement, dated as of September 30, 2020, between PDL BioPharma, Inc. and LENSAR, Inc
PDL BIOPHARMA, INC.
Biotechnology
DE
2020
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
PDL BIOPHARMA, INC.
Biotechnology
2020
Offer Letter between the Company and Ed Imbrogno
PDL BIOPHARMA, INC.
Biotechnology
2019
Offer Letter between the Company and Dominique Monnet, executed August 31, 2017
PDL BIOPHARMA, INC.
Biotechnology
2017
Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked * * * and has been filed separately with the Securities and Exchange Commission pursuant...
PDL BIOPHARMA, INC.
Biotechnology
NY
2016
932 Southwood BoulevardIncline Village, NV 89451Phone: (775) 832-8500Fax: (775) 832-8502
PDL BIOPHARMA, INC.
Biotechnology
NV
2015
932 Southwood BoulevardIncline Village, NV89451Phone:(775) 832-8500Fax ###-###-####
PDL BIOPHARMA, INC.
Biotechnology
NV
2012
Offer Letter between the Company and Danny Hart, dated January 11, 2010
PDL BIOPHARMA, INC.
Biotechnology
2011
PATENTLICENSE AGREEMENT between PROTEINDESIGN LABS, INC. and MEDIMMUNE,INC.
PDL BIOPHARMA, INC.
Biotechnology
CA
2011
- 1 -
PDL BIOPHARMA, INC.
Biotechnology
2010
AMENDED AND RESTATED PATENT LICENSING MASTER AGREEMENT (QUEEN PATENTS)
PDL BIOPHARMA, INC.
Biotechnology
CA
2010
PDL BIOPHARMA, INC. 2005 EQUITYINCENTIVE PLAN (AMENDED AND RESTATEDEFFECTIVE JUNE 4, 2009) PDL BIOPHARMA, INC.
PDL BIOPHARMA, INC.
Biotechnology
CA
2009
CONFIDENTIAL PROVISIONS MARKED
PDL BIOPHARMA, INC.
Biotechnology
CA
2009
CONFIDENTIAL PROVISIONS MARKED
PDL BIOPHARMA, INC.
Biotechnology
CA
2009
CONFIDENTIAL PROVISIONS MARKED EXHIBIT 10.26 (CONFIDENTIAL) AMENDMENT NO. 2 TO THE PATENT LICENSING MASTER AGREEMENT
PDL BIOPHARMA, INC.
Biotechnology
2009
AMENDMENT TO THE RIGHTS AGREEMENT
PDL BIOPHARMA, INC.
Biotechnology
2009
CONFIDENTIALPROVISIONS REDACTED
PDL BIOPHARMA, INC.
Biotechnology
NJ
2008
PDL BIOPHARMA, INC. RESTRICTEDSTOCK AGREEMENT
PDL BIOPHARMA, INC.
Biotechnology
CA
2006
Exhibit 10.55 to Form 10-K CONFIDENTIAL PROVISIONS REDACTED
PDL BIOPHARMA, INC.
Biotechnology
2006
Exhibit 10.54 to Form 10-K CONFIDENTIAL PROVISIONS REDACTED
PDL BIOPHARMA, INC.
Biotechnology
2006
ASSETPURCHASE AGREEMENT CENTOCOR,INC (SELLER) ESPPHARMA, INC. (BUYER) January 31,2005
PDL BIOPHARMA, INC.
Biotechnology
NY
2005
ICOS CORPORATION MANUFACTURING AGREEMENT
PDL BIOPHARMA, INC.
Biotechnology
2005
AMENDEDAND RESTATED WORLDWIDE AGREEMENT
PDL BIOPHARMA, INC.
Biotechnology
CA
2005
CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
PDL BIOPHARMA, INC.
Biotechnology
2004
Protein Design Labs, Inc. Retiree Health Care Plan Effective June 1, 2003
PDL BIOPHARMA, INC.
Biotechnology
CA
2004
CONFIDENTIAL PROVISIONS MARKED EXHIBIT 10.49 (CONFIDENTIAL)
PDL BIOPHARMA, INC.
Biotechnology
CA
2004
CONFIDENTIAL PROVISIONS MARKED EXHIBIT 10.48 (CONFIDENTIAL)
PDL BIOPHARMA, INC.
Biotechnology
CA
2004
AMENDMENT NO. 1 TO THE HERCEPTINLICENSE AGREEMENT
PDL BIOPHARMA, INC.
Biotechnology
2004
EXHIBIT10.46 (CONFIDENTIAL)
PDL BIOPHARMA, INC.
Biotechnology
2004
CONFIDENTIALPROVISIONS MARKED
PDL BIOPHARMA, INC.
Biotechnology
2004
Financial statements of businesses acquired
PDL BIOPHARMA, INC.
Biotechnology
2003
Financial statements of businesses acquired
PDL BIOPHARMA, INC.
Biotechnology
2003
Financial statements of businesses acquired
PDL BIOPHARMA, INC.
Biotechnology
CA
2003